Mass General Brigham researchers find pTau217 blood test predicts Alzheimer’s years before brain scans
Updated
Updated · SciTechDaily · Apr 25
Mass General Brigham researchers find pTau217 blood test predicts Alzheimer’s years before brain scans
14 articles · Updated · SciTechDaily · Apr 25
A study of 317 cognitively healthy adults aged 50 to 90 tracked over eight years showed that elevated pTau217 levels forecast amyloid buildup and cognitive decline before PET scans detect abnormalities.
The findings suggest blood-based biomarkers like pTau217 could enable earlier, less invasive Alzheimer’s risk identification, potentially improving prevention trial screening and future clinical monitoring.
While not yet ready for routine clinical use, this research builds on recent FDA approval of Alzheimer’s blood tests and may lead to more accessible, cost-effective early detection methods.
A new blood test can predict Alzheimer's. When will it be available for routine check-ups?
Early Alzheimer's detection is here. Could this knowledge cause more harm than good for healthy people?
New Alzheimer's tests promise early detection. But will they be fair and accessible to everyone?
This biomarker slashes Alzheimer's trial costs. How will this accelerate the search for a cure?
We can now predict Alzheimer's decades early. Is our healthcare system prepared for the results?
Breakthrough pTau217 Blood Test Revolutionizes Early Alzheimer's Detection and Treatment
Overview
In May 2025, the FDA approved the Lumipulse G blood test, which measures specific protein ratios to detect Alzheimer's disease years before symptoms appear. Supported by a key study showing its strong predictive power, the test performs with high accuracy in research but faces challenges in real-world use due to factors like kidney impairment, leading to false positives and emotional distress. To reduce risks, the test uses a two-cutoff system. Early detection enables timely treatment with drugs like lecanemab, which slows disease progression. The test also improves access by offering a cheaper, less invasive alternative to PET scans, while transforming clinical trials and research. However, barriers and ethical considerations remain for widespread adoption.